Readystate Asset Management LP Vertex Pharmaceuticals Inc Call Options Transaction History

Readystate Asset Management LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $7.45 Million - $8.19 Million	16,200 Added 1012.5%	17,800 $8.28 Billion
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $10.8 Million - $13.3 Million	-27,400 Reduced 94.48%	1,600 $750 Million
Q1 2024 May 10, 2024	BUY	$407.69 - $446.08 $7.95 Million - $8.7 Million	19,500 Added 205.26%	29,000 $12.1 Billion
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $3.05 Million - $3.66 Million	8,900 Added 1483.33%	9,500 $3.87 Billion
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $188,652 - $211,146	600 New	600 $211 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Readystate Asset Management LP with notifications on news.